TYRA | Tyra Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	15.14 - 15.75
52 Week Range	11.24 - 29.60
Beta	0.88
Implied Volatility	119.22%
IV Rank	51.85%
Day's Volume	50,803
Average Volume	323,361
Shares Outstanding	50,602,994
Market Cap	774,225,808
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-15

Valuation
Profitability
Growth
Health
P/E Ratio	-9.50
Forward P/E Ratio	N/A
EPS	-1.61
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	USA
Website	TYRA

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

TYRA's peers: CMPX, MGNX, PHVS, RANI, RAPT, TARS, TNGX, TRDA, CNTB, XLO, MLYS, GRCL, THRX, GLUE, DSGN, ERAS, HOWL, IKNA, STOK, PMVP, MOLN, IPSC, EWTX, CCCC, CGEM, URGN, VALN, VERA, VIGL, PEPG, SNTI, VANI, ZVRA

*Chart delayed

Analyzing fundamentals for TYRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see TYRA Fundamentals page.

Watching at TYRA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TYRA Technicals page.